We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | NASDAQ:AYTU | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0643 | 2.26% | 2.9043 | 2.56 | 2.97 | 2.92 | 2.87 | 2.87 | 6,144 | 01:00:00 |
| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| |||||||||
Combined public offering price
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | |
Proceeds, before expenses, to us
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | |
| | |
Page
|
| |||
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-3 | | | |
| | | | S-10 | | | |
| | | | S-12 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-16 | | | |
| | | | S-20 | | | |
| | | | S-24 | | | |
| | | | S-24 | | | |
| | | | S-24 | | | |
| | | | S-24 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 11 | | | |
| | | | 18 | | | |
| | | | 20 | | | |
| | | | 22 | | | |
| | | | 25 | | | |
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT (amphetamine) | | | Treatment of ADHD in patients 6 years and older | | | January 2016 | | | May 2016 | |
Cotempla XR-ODT (methylphenidate) | | | Treatment of ADHD in patients 6 to 17 years old | | | June 2017 | | | September 2017 | |
|
Public offering price per share of common stock (or pre-funded warrants in lieu thereof) and accompanying Warrant
|
| |
|
| | | $ | 0.43 | | | |||
|
Net tangible book value per share as of March 31, 2022
|
| | | $ | (0.66) | | | | | | | | |
|
Increase per share attributable to this offering
|
| | | $ | 0.43 | | | | | | | | |
|
As-adjusted net tangible book value per share after giving effect to this offering
|
| | | | | | | | | $ | (0.23) | | |
|
Dilution per share to new investors(1)(2)
|
| | | | | | | | | $ | (0.66) | | |
Name
|
| |
Number of
shares |
| |
Number of
pre-funded warrants |
| |
Number of
Warrants |
| |||||||||
Cantor Fitzgerald & Co.
|
| | | | 13,978,780 | | | | | | 1,137,500 | | | | | | 15,116,280 | | |
Cannaccord Genuity LLC
|
| | | | 7,527,034 | | | | | | 612,500 | | | | | | 8,139,534 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | ||
Total
|
| | | | 21,505,814 | | | | | | 1,750,000 | | | | | | 23,255,814 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 11 | | | |
| | | | 18 | | | |
| | | | 20 | | | |
| | | | 22 | | | |
| | | | 25 | | | |
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT (amphetamine) | | | Treatment of ADHD in patients 6 years and older | | | January 2016 | | | May 2016 | |
Cotempla XR-ODT (methylphenidate) | | | Treatment of ADHD in patients 6 to 17 years old | | | June 2017 | | | September 2017 | |
Adzenys ER (amphetamine) oral suspension | | | Treatment of ADHD in patients 6 years and older | | | September 2017 | | | February 2018 | |
1 Year AYTU BioPharma Chart |
1 Month AYTU BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions